Supplement Methods

Literature search and inclusion

Database search keywords for Generalized Anxiety Disorder (GAD) included: ("generalized anxiety disorder", OR ("GAD")) AND ("voxel-based morphometry", OR ("VBM"), OR ("gray matter")).

Database search keywords for Fear-related Anxiety Disorders (FAD) included: ("social anxiety disorder", OR ("social phobia"), OR ("SAD"), OR ("specific phobia"), OR ("panic disorder"), OR ("Phobia"), OR ("agoraphobia")) AND ("voxel-based morphometry", OR ("VBM"), OR ("gray matter")).

Database search keywords for Major Depressive Disorder (MDD) included: "Depression" AND ("voxel-based morphometry", OR ("VBM"), OR ("gray matter")). Broad search terms were used to prevent missing any relevant studies. Additionally, we inspected reference lists of relevant reviews and original studies to identify further eligible articles.

Key inclusion criteria were (1) neuroimaging case control design studies comparing brain structure between a group of patients with GAD, FAD or MDD with healthy controls (HC), and (2) whole-brain VBM between-group comparisons (including null findings) reported. Studies were excluded if they (1) were non-empirical studies (e.g., review, meta-analysis, meeting abstract); (2) were not published in English; (3) did not report direct comparison between a patient and healthy control (HC) group; (4) did not report whole-brain results (i.e., only ROI results); (5) did not provide sufficient data (e.g., peak coordinates, etc.) even after contacting the authors of the original study. In case the same HC reference group was employed for several subgroup comparisons, only the combined result was included in the meta-analysis.

Meta-analysis

SDM procedures

For each article group, raw statistical maps or coordinates from cluster peaks including their effective sizes (t-values, representing the GMV differences between patients and controls) and sample sizes were entered into the SDM-PSI to be preprocessed using a 20 mm full width half maximum (FWHM) anisotropic Gaussian kernel and 2 mm voxel size. In this step, SDM converts *t*-values into Hedge's g effect sizes and their variances using evaluated algorithms (1) in case raw maps for the original study are not available. SDM conducts multiple imputation to estimate the lower and upper bounds of possible effect sizes for each study using an anisotropic Gaussian kernel. Then in the mean analysis, SDM-PSI conducts unbiased maximum likelihood estimation (MLE) of effect sizes and associated standard errors by imputing the effect size maps of individual studies for each group based on MetaNSUE algorithms (2, 3). To prevent a single study or few studies from driving the results, SDM uses a leave one out jackknife procedure. The number of imputations for mean analysis was set to 50 by default. Finally, SDM-PSI allows a Freedman-Lane-based permutation test at the subject level to perform voxel-wise tests of statistical significance while controlling familywise error rate (FWER) using threshold-free cluster enhancement (TFCE) (4). Details of these procedures are provided in the corresponding methodological publications (5, 6) and the SDM-PSI reference manual (https://www.sdmproject.com/manual/).

Transdiagnostic meta-analysis

A transdiagnostic meta-analysis of VBM studies across GAD (9 studies, 226 patients), FAD (23 studies, 996 patients) and MDD (46 studies, 2575 patients) was conducted and thresholded at TFCE-based FWE corrected p < 0.05.

Partly resembling the results of a previous transdiagnostic meta-analysis including schizophrenia, bipolar disorder, major depression, substance use disorder and a pooled group of anxiety disorders (7), we observed decreased right insular cortex volume in the overarching pooled meta-analysis (**Figure. S1**). However, the number of MDD studies was at least two times larger than the number of GAD or FAD studies and the imbalance may strongly bias the results in favor of the MDD-related alterations (see also results in the main text demonstrating reduced right mid-insula volumes in MDD but not FAD or GAD, **Figure 2A, B, C**), while the conjunction approach in our main analyses would only identify regions showing convergent alterations across the disorder categories.

Supplement Results

<u>64</u> 1	Number	(female)	Age ((years) Duration Sc ————————————————————————————————————	Scanner/ <i>p</i> value		G (* 1)			
Study	GAD	НС	GAD	НС	(years)	Medication	Comorbidity	FWHM (mm)	<i>p</i> value	Summary findings
						Madiantian land				GAD < HC: L/R
Chen et al.		/>								sgACC/vmPFC, L
2020 *	72 (41)	57 (30)	39.04	40.91	4.56	index: 1.67 \pm	0	31/8	<i>p</i> < 0.05 (GRF)	ITG, R Insula, R
						0.69				dmPFC
							12 MDD, 2			
							dysthymia,			
Hilbert et al.	19 (16)	24 (17)	33.47	32.25	NA	Drug naïve	13 other	3T/8	<i>p</i> < 0.05 (FWE)	GAD > HC: R Striatum
2015							anxiety			
							disorders			

Table S1. Demographic and clinical characteristics of the 9 GAD VBM datasets included in the meta-analysis.

Kim et al.	16 (6)	16 (6)	22.00	22.50	5 (0)	Medicated	NTA		<i>p</i> < 0.001	Precuneus, L dlPFC, L
2018	10 (0)	16 (6)	55.00	52.50	5.00	(<i>n</i> = 10)	NA	31/0	(uncorr)	OFG, L SOG, L Insula,
										L STG, L mPFC
Liao et al.	26 (13)	25 (12)	16.85	16.72	NA	Drug naïve	0	3T/8	p < 0.05 (FWE)	GAD > HC: R
2014	20 (10)		10100	102			Ŭ	01/0	p (0.00 (2 + 2)	Putamen
Ma et al.						Drug-free (> 6			p < 0.05	GAD < HC: R
2010	21 (9)	20 (10)	34.92	35.96	2.39		0	3T/6		Precentral
2019						month)			(AlphaSim)	gyrus, R SFG
										GAD < HC: R
Makovac et										Supramarginal
al 2016	19 (16)	19 (16)	30.00	29.20	16.78	Medicated $(n = 2)$	0	1.5T/8	<i>p</i> < 0.05 (FWE)	gyrus/postcentral
uii 2010										gyrus, L Postcentral
										gyrus, R Precentral

										gyrus, L Supramarginal
										gyrus
										GAD < HC: L
Moon et al.	22(0)	22 (9)	37.00	33 40	4 90	NA	NA	317/8	<i>p</i> < 0.001	Midbrain, L Thalamus,
2014	22 (9)	22 (9)	37.00	55.40	4.90	INA	INA	51/8	(uncorr)	L Hippocampus, L
										Insula, L STG
Schienle et al., 2011	16 (16)	15 (15)	22.90	23.70	3.10	Drug naïve	0	3T/12	<i>p</i> < 0.05 (FWE)	
										GAD > HC: R
Strawn et	15 (8)	28 (17)	12.00	12.00	ΝA		other anviety	<i>4</i> Τ /8	<i>p</i> < 0.001	precentral gyrus, R
al., 2013	15 (6)	20 (17)	13.00	15.00			disordors	41/0	(uncorr)	Precuneus; GAD < HC:
							uisorders			R PCC, L OFG

Abbreviations: ACC, anterior cingulate cortex; dlPFC, dorsolateral prefrontal cortex; dmPFC, dorsomedial prefrontal cortex; FWE, family-wise error; FWHM, full width at half maximum; GAD, generalized anxiety disorder; GRF, Gaussian random field; HC, healthy controls; ITG, inferior temporal gyrus; L, left hemisphere; mPFC, medial prefrontal cortex; NA, not available; OFG, orbitofrontal gyrus; PCC, posterior cingulate cortex; R right hemisphere; SFG, superior frontal gyrus; sgACC, subgenual anterior cingulate cortex; SOG, superior occipital gyrus; STG, superior temporal gyrus; uncorr, uncorrected; VBM, voxel-based morphometry; vmPFC ventromedial prefrontal cortex. * Studies that provided original whole-brain *t*-maps.

Char Iar	Disorder	Number	(female)	Age (y	vears)	Duration	Mallardar		Scanner/		G
Study	type	Patients	НС	Patients	НС	(years)	Medication	Comorbidity	FWHM (mm)	<i>p</i> value	Summary findings
								8 MDD, 2			
Dee								MDD + PD, 10			
Bas-		174 (102)	212 (100)	20, 60	22.40	15.00	Medicated	GAD, 3 GAD +	277/7 5	<i>p</i> < 0.05	
Hoogendam	SAD	174 (102)	213 (106)	30.60	32.40	15.80	(n = 24)	SP, 2 GAD +	31//.5 mm	(FWE)	
et al. 2017 *								PD, 3PD, 6 SP,			
								26 unknown			
Cheng et al.				22.20	26.20	2.00		0		<i>p</i> < 0.05	
2015	SAD	20(7)	30 (9)	23.30	26.20	3.99	Drug naive	0	31/8 mm	(FWE)	
Frick et al.		40 (24)	20 (1.6)	22.00	22.70			10 GAD; 7 SP;	N.A. (0	<i>p</i> < 0.05	SAD > HC: L/R
2014	SAD	48 (24)	29 (16)	33.80	23.70	NA	Drug naive	3 MDD; 2 PD	NA/8 mm	(corr)	Lingual gyrus, L

Table S2. Demographic and clinical characteristics of the 32 FAD VBM datasets included in the meta-analysis.

FFG, R Secondary

occipital cortex

T.1 1							M. 1 1	1 (MDD, 7 CD		<i>p</i> <	
Irle et al.	SAD	67 (35)	64 (31)	31.00	32.00	15.00	Medicated	16 MDD; / SP;	3T/8 mm	0.001	
2014							(n = 6)	5 PD; 1 GAD			
										(uncorr)	
Kawaguchi		12 (9)	18 (0)	26.20	22.80	22.20	NT A		277/0	<i>p</i> < 0.05	
et al. 2016	SAD	13 (8)	18 (0)	36.20	33.80	23.30	NA	4 MDD; I PD	31/8 mm	(FWE)	
											$SAD > UC \cdot P$
										<i>p</i> < 0.05	SAD > IIC. K
Liao et al.	SAD	18 (6)	18 (5)	22 70	21.90	4 10	Drug naïve	0	3T/8 mm	(AlphaSi	mPFC;
2011	5/10	10 (0)	10(5)	22.70	21.90	4.10	Drug harve	Ū	51/6 1111	(Anphaor	SAD < HC: L PHG,
										m)	P ITC
											KIIO
Meng et al										<i>p</i> < 0.05	SAD < HC· L/R
meng et al.	SAD	20 (6)	19 (6)	21.80	21.60	4.21	Drug naïve	0	3T/12 mm	(AlphaSi	
2013										m)	Thalamus, R

Amygdala, R Precuneus SAD > HC: R 11 MDD;5 *p* < 0.05 supramarginal and Talati et al. Medicated GAD; 4 SP, 1 (nonstati SAD 33 (9) 1.5T/8 mm 37 (19) 31.50 31.40 NA angular cortices; 2013 (n = 9) OCD, 1 DUD, onary SAD < HC: L 2 AUD corr) temporal pole SAD > HC: L Superior parietal p < 0.05Tükel et al. and precuneus, R 1.5T/8 mm SAD 27 (15) 27 (15) 27.70 27.70 13.80 Drug naïve (AlphaSi 0 2015 * middle and inferior m) temporal areas, R

FFG

Zhao at al										<i>p</i> <	SAD < HC: L/R
2017	SAD	24 (9)	41 (15)	24.50	27.10	7.60	Drug naïve	0	3T/8 mm	0.001	Putamen, L/R OFC,
2017										(FDR)	L/R Thalamus
											PD < HC: L/R
											dmPFC, R vmPFC,
											R Amygdala, R
A 1							Malandal	13 AG, 3		.0.05	ACC, L/R STG,
Asami et al.	PD	24 (15)	24 (15)	37.03	37.01	3.90	Medicated	MDD, 1	1.5T/12 mm	<i>p</i> < 0.05	L/R Insula, L/R
2009							(n = 36)	dysthymia		(FDR)	Lateral
											occipitotemporal
											gyrus, L cerebellar

vermis

										p <	
Kunas et al.	PD	143 (89)	178 (101)	33.65	31.63	NA	Drug naïve	51 MDD	3T/8 mm	0.001	PD < HC: L MTG
										(uncorr)	
										<i>p</i> <	PD < HC: L OFC,
Lai & Wu,	PD	30 (19)	21 (11)	47.03	41.14	NA	Drug naïve	13 AG	3T/7.5 mm	0.005	L IFG, R Insula, L
2012										(FWE)	STG
Lai & Wu,	DD	52 (29)	54 (20)	42.28	40.38	5 25		0	2T/7 5 mm	<i>p</i> < 0.05	PD < HC: R IFG R
2015	PD	33 (28)	34 (29)	45.28	40.38	5.55	Drug harve	0	51/7.5 11111	(FWE)	Insula
Massana et	DD	10 (11)	18 (10)	26.80	2670	NT A		15 4 0	1.57/10	<i>p</i> < 0.05	
al. 2003	PD	18 (11)	18 (10)	30.80	36.70	NA	Drug naive	15 AG	1.51/12 mm	(corr)	PD < HC: L PHG
Na et al.	DD	22 (0)	22 (11)	40.10	40.10		D	12.4.0	25.0	<i>p</i> < 0.05	PD < HC: L/R
2013	PD	22 (9)	22 (11)	40.18	40.18	NA	Drug naive	12 AG	31/8 mm	(FWE)	SOG, cuneus
Protopopescu	DD	10 (0)	22 (11)	22.50	29.70		Medicated			<i>p</i> < 0.05	PD > HC:
et al. 2006	PD	10 (6)	23 (11)	33.50	28.70	NA	(n = 1)	2 AG	31/12 mm	(GRF)	Brainstem

								16 AG, 1 SAD,			
Sobanski et										p < 0.05	PD < HC: R MTG,
	PD	17 (9)	17 (9)	34.90	33.10	7.90	NA	1 GAD, 2 AD,	1.5T/12 mm		
al. 2010										(FWE)	R OFC
								2 PPD			
											PD > HC: L/R
								3 MDD. 2			Cuneus, lingual: PD
								5 1100, 2			Cullous, Inigual, I D
Talati et al.							Medicated	GAD,5 SP, 2		p < 0.05	< HC: R
	PD	16 (13)	20 (9)	31.80	31.40	13.40			1.5T/8 mm		
2013							(n = 9)	OCD,4 DUD,4		(corr)	precentral,
								AUD			postcentral, R
											middle cingulate
											PD > HC: L Insula
								14 AG, 3		<i>p</i> <	
Uchida et al.							Medicated				and STG, L
	PD	19 (16)	20 (16)	37.05	36.45	8.34		MDD, 2	1.5T/12 mm	0.001	
2008							(n = 15)	duathumic		(110,00,000)	Midbrain and pons;
								aystnymia		(uncorr)	PD < HC: R ACC

PD < HC: L/R

Yoo et al.						• • • •	Medicated			<i>p</i> < 0.05	Putamen, R
2005	PD	18 (9)	18 (7)	33.30	32.00	3.60	(n = 10)	0	3T/8 mm	(corr)	Precuneus gyrus, R
											ITG, L STG, L SFG
											Specific phobia >
											HC: R ACC, R
Hilbert et al.	SD	50 (45)	27 (28)	22.05	22.76	NA	Drug poïvo	0	1.5T/12.mm	<i>p</i> < 0.05	Calcarine sulcus, R
2015	Sr	<i>39</i> (4 <i>3)</i>	57 (28)	23.93	22.70	NA	Drug narve	0	1.51/12 1111	(FWE)	FFG, L medial
											OFC, L Precuneus,
											R Vermis
Sabiantai at										<i>p</i> <	
al 2012	SP	45 (25)	41 (23)	30.39	29.24	16.69	Drug naïve	0	3T/8 mm	0.001	
al. 2013										(uncorr)	

Abbreviations: ACC, anterior cingulate cortex; AD, adjustment disorder with mixed disturbance of emotions and conduct; AG, agoraphobia; AUD, alcohol use disorder; corr, corrected; dlPFC, dorsolateral prefrontal cortex; dmPFC, dorsomedial prefrontal cortex; DUD, drug use disorder; FAD, fear-related anxiety disorder; FDR, false discovery rate; FFG, fusiform gyrus; FWE, family-wise error; FWHM, full width at half maximum; GRF, Gaussian random field; HC, healthy controls; IFG, inferior frontal gyrus; IOG, inferior occipital gyrus; IPL, inferior parietal lobule; ITG, inferior temporal gyrus; L, left hemisphere; LOC, lateral occipital cortex; MCC, medial cingulate cortex ; MDD, major depressive disorder; MFG, medial frontal gyrus; MOG, middle occipital gyrus; mPFC, medial prefrontal cortex; MTG, middle temporal gyrus; NA, not available; OCD, obsessive-compulsive disorder; OFC, orbitofrontal cortex; PCC, posterior cingulate cortex; PCG, paracingulate gyrus; PD, panic disorder; PHG, parahippocampal gyrus; PPD, paranoid personality disorder; PTSD, post-traumatic stress disorder; R right hemisphere; SAD, social anxiety disorder; SFG, superior frontal gyrus; SMA, supplementary motor area; SOG, superior occipital gyrus; SP, specific phobia; STG, superior temporal gyrus; TOFC, temporal-occipital fusiform cortex; uncorr, uncorrected; VBM, voxel-based morphometry; vmPFC ventromedial prefrontal cortex.

* Studies that provided original whole-brain *t*-maps.

	Number	(female)	Age (y	years)	Derestier			Scanner/		
Study		нс	MDD	ШС	- Duration	Medication	Comorbidity	FWHM	p value	Summary findings
	MDD	нс	MDD	нс	(years)			(mm)		
										MDD < HC: R PHG, L/R
Abe et al.	21 (10)	42 (20)	49.10	48.00	< 00	Medicated	0	1.577/6.0000		Middle frontal gyrus, L IOG,
2010	21 (10)	42 (20)	48.10	48.00	6.00	(n = 19)	0	1.51/6 mm	<i>p</i> < 0.05 (FDR)	L SMA, R STG, L Parietal
										lobe, L/R ACC
										MDD > HC: L Postcentral
										gyrus, R Postcentral gyrus, L/R
Ahn et al.									<i>p</i> < 0.05	Parieto-occipital cortex, L/R
2016	34 (29)	26 (19)	32.43	31.40	NA	NA	NA	3T/8 mm	(AlphaSim)	Putamen, R Thalamus, L/R
										Hippocampus, L/R
										Cerebellum;

Table S3. Demographic and clinical characteristics of the 46 MDD VBM datasets included in the meta-analysis.

MDD < HC: L/R OFC, R

dmPFC, R dorsal ACC, L/R

MOG, L Cuneus

Amico et al.						Medicated				
	33 (14)	64 (28)	32.00	30.40	3.40		0	1.5T/8 mm	p < 0.05 (FWE)	
2011						(n = 27)				
Arnone et al										MDD < HC: L/R
Amone et al.	39 (27)	66 (46)	36.30	32.10	14.30	Drug naïve	0	1.5T/8 mm	<i>p</i> < 0.05 (FWE)	Hippocampus/PHG, L/R
2013										FFG/ITG, L/R Ventral striatum
										MDD < HC: R Cingulate
Bergouignan	20 (17)	21 (14)	33.16	28.21	8.45	Medicated	0	1.5T/8 mm	p < 0.05 (FDR)	gyrus, R MTG, R Posterior
et al. 2009	20 (17)			20121	01.0	(n = 20)	ũ		p (0.00 (1210)	lobe, R SPL, R PHG, L Inferior

semi-lunar lobule

Biedermann et						Medicated				
al., 2015	46 (34)	35 (22)	50.80	46.40	NA	(n = 24)	NA	1.5T/8 mm	<i>p</i> < 0.05 (FWE)	
Cai et al.,	23 (10)	23 (10)	30.00	30.00	1 35	NΔ	0	3T/8 mm	<i>p</i> < 0.001	MDD < HC. IEG
2015	25 (10)	25 (10)	50.00	50.00	ч. <i>33</i>	IVA	0	51/6 1111	(uncorr)	
Chaney et al.	37 (21)	46 (28)	40.22	36.61	9 65	Medicated	0	3T/10 mm	n < 0.05 (FWF)	_
2014	57 (21)	40 (20)	40.22	50.01	7.05	(n = 24)	0	51/10 mm	<i>p</i> < 0.05 (1 (12)	
Chen et al.	27 (14)	28 (14)	33.00	33.00	6 58	Drug naïve	0	3T/6 mm	<i>p</i> < 0.05	MDD > HC: R Postcentral
2016 *	27 (11)	20 (11)	55.00	55.00	0.50		0	51/0 1111	(AlphaSim)	gyrus
Chen et al.						Medicated			<i>n</i> < 0.001	MDD < HC: R Occipital
2020	22 (18)	22 (18)	28.70	27.40	4.40	(n = 17)	0	3T/8 mm	(uncorr)	fusiform gyrus, L Postcentral
						()			()	gyrus
		510							0.001	MDD < HC: R
Dannlowski	171 (105)	512	38.60	33.30	NA	Medicated	0	3T/8 mm	<i>p</i> < 0.001	PHG/HC/amygdala, R
et al. 2015		(289)				(n = 171)			(Monte Carlo)	Insula/putamen, IFG, L

Lingual gyrus, FFG,

Cerebellum, IOG, L/R MCC, L

STG/MTG, L/R Thalamus

										MDD < HC: L/R ITG, L IFG,
Fang et al. 2015	20 (8)	18 (8)	59.20	59.10	3.60	NA	NA	1.5T/8 mm	<i>p</i> < 0.05 (corrected)	L Precuneus, R MCC, R FFG,
										R Cuneus
Förster et al.							19 anxiety			
2020	63 (33)	46 (22)	42.43	45.35	NA	NA	disorders	3T/8 mm	<i>p</i> < 0.05 (FWE)	
Grieve et al.	102 (54)	24(1c)	22.90	21.50	11.20	NTA	0	217/0		MDD < HC: R Rectal gyrus, R
2013	102 (54)	34 (16)	33.80	31.50	11.30	NA	0	31/8 mm	<i>p</i> < 0.05 (FDR)	IFG, L FFG, R ITG, L MTG,
Hagan et al.	100 (01)		15.54	15.65		Medicated	0			
2015	109 (81)	36 (26)	15.56	15.65	NA	(n = 37)	0	31/7 mm	<i>p</i> < 0.05 (FWE)	
Inkster et al.	145 (04)	183	40.45	48.00	14.20	NTA	0	1.577/10	- 0.05 (EWE)	
2011	145 (94)	(110)	49.43	48.00	14.30	INA	U	1.51/10 mm	p < 0.05 (FWE)	MIDD < HC: K SPL

Kandilarova						Medicated				
et al. 2019	39 (29)	42 (29)	47.70	42.60	10.80	(n = 37)	0	3T/8 mm	<i>p</i> < 0.05 (FDR)	MDD < HC: L MFG/ACC
Klauser et al. 2015	56 (40)	33 (21)	34.02	34.71	10.29	Medicated (n = 33)	0	1.5T/10 mm	p < 0.05 (permutation)	MDD < HC: L/R vmPFC
										MDD < HC: L/R Midbrain,
										L/R sgACC, L/R Thalamus, L
						Medicated				Short insular gyrus, L/R
Lee et al. 2011	47 (42)	51 (45)	46.00	45.70	3.89	(n - 27)	0	1.5T/10 mm	<i>p</i> < 0.05 (FDR)	Nucleus accumbens, L/R
						(n - 27)				Amygdala, L/R Hippocampus,
										L/R FFG, L Lingual gyrus, L/R

MTG, R STG, L/R Cerebellum

										MDD < HC: L/R Middle
										frontal gyrus, L/R Rectal
										gyrus, L/R Short and long
						Medicated				insula gyrus, L/R ACC, MCC,
Lee et al. 2020	20 (20)	21 (21)	42.50	42.30	9.50	(n = 20)	0	1.5T/10 mm	<i>p</i> < 0.05 (FDR)	L/R PCC, L/R Thalamus, L/R
						(0)				Hypothalamus, L/R Amygdala,
										L/R Hippocampus, L/R PHG,
										L Lingual gyrus, L/R STG,
										MTG, ITG
										MDD < HC: R ACC, R STG,
Leung et al.	17 (17)	17 (17)	45.50	45.80	7.00	Medicated	NA	1.5T/12 mm	<i>p</i> < 0.001	R SFG, L/R MFG, R FFG, R
2009			J.JU	-J.00	7.00	(n = 17)	INA	1.51/12 1111	(uncorr)	IFG, L/R Precentral gyrus, L

MCC, L Insula, L Angular

gyrus, L Precuneus, L MTG, L MCC, PCC MDD > HC: L L Caudate, R ITG, L Cerebellum, L Lingual Lu et al. 2018 76 (44) 86 (43) 34.27 33.35 3.74 Drug naïve 0 3T/8 mm *p* < 0.05 (GRF) gyrus; MDD < HC: L/R PHG/Hippocampus, R MTG MDD > HC: R MOG; MDD < Lu et al. 2019 3T/8 mm 30 (13) 48 (30) 23.98 21.50 2.56 Drug naïve 0 *p* < 0.05 (GRF) HC: L SPL MDD < HC: R ACC, R SMA, Medicated R Precentral gyrus, R Mak et al. *p* < 0.001 17 (17) 17 (17) 45.50 45.80 NA 0 1.5T/8 mm 2009 (n = 17) (uncorr) Temporal pole, L Angular gyrus, L Precuneus

Modinos et al										MDD < HC: L/R Orbital gyrus,
2014	23 (20)	46 (14)	44.60	25.30	NA	NA	NA	1.5T/8 mm	<i>p</i> < 0.05 (FWE)	R MFG, L ACC, L/R IPL, R
2011										MTG, L MFG
Nakano et al.	36 (22)	54 (27)	40.00	45 40	5 56	Medicated	0	1 5T/8 mm	n < 0.05 (EWE)	MDD < HC: R mPFC, R
2014	50 (22)	54 (27)	49.00	43.40	5.50	(n = 31)	0	1.5178 mm	$p < 0.05 (\Gamma WE)$	superior OFC
Onel et al		358				Medicated	Comorbidity			MDD < HC: R
2010	506 (308)	(178)	49.14	52.57	6.73	(n - 441)	index: 1.65 \pm	3T/8 mm	<i>p</i> < 0.05 (FWE)	Insula/STG/MTG, L
2019		(178)				(11 – 441)	0.81			SFG/MFG, R MFG/IFG
Donnakoak at							18 anxiety		n < 0.05	
	26 (23)	26 (23)	15.40	14.70	NA	Drug naïve	disorder; 5	3T/7 mm	p < 0.05	
al. 2014							ADHD		(permutation)	
	12 (0)	15 (10)	24.40	22.70		D	0	200	<i>p</i> < 0.001	
Qiu et al. 2016	12 (8)	15 (10)	34.40	33.70	NA	Drug naive	0	31/8 mm	(uncorr)	MDD < HC: K Cingulate gyrus

MDD < HC: L/R

Hippocampus, FFG, Lingual

Dadliah at al						Madiantad	25 opviotu		n < 0.05	gyrus, L Supramarginal gyrus,
Keunch et al.	58 (36)	58 (37)	37.60	37.70	10.98	Medicated	55 anxiety	3T/8 mm	<i>p</i> < 0.05	IPL, L/R MCC, ACC, mPFC,
2014						(n = 52)	disorder		(AlphaSim)	SMA, R Middle frontal gyrus,
										SFG, L/R Precunues, L
										MTG/STG, L Caudate
Redlich et al. 2018	20 (15)	21 (12)	16.00	16.57	2.63	Medicated $(n = 8)$	0	3T/6 mm	<i>p</i> < 0.05 (FWE)	
							2 AUD; 2			
Rodríguez-						M. 1 1	AG; 1 AD; 1			
Cano et al.	32 (20)	64 (38)	48.68	46.03	10.94	Medicated	anxiety	1.5T/4 mm	<i>p</i> < 0.05 (FWE)	MDD < HC: L FFG
2014						(n = 28)	disorder; 1			
							dysthymia			

Salvadore et		107				Medicated				
	58 (37)		38.80	36.20	18.40		0	3T/11 mm	p < 0.05 (FWE)	MDD < HC: L/R SFG, L MFG
al. 2011		(60)				(n = 44)				
										MDD > HC: R Cerebellum, R
										Rolandic operculum, R SFG, R
										Precuneus, L IFG, R
										Amygdala;
Scheuerecker	12 (2)	15 (5)	27.00	25.50	4.26	Dura a sina	0	217/0	<i>p</i> < 0.001	MDD < HC: L IFG, L Inferior
et al. 2010	13 (3)	15 (5)	37.90	55.50	4.30	Drug naive	0	51/8 mm	(uncorr)	frontal operculum, L MTG, R
										Postcentral gyrus, L IPL, L
										STG, L Postcentral gyrus, L
										Rolandic operculum, R IOG, L
										IFG, ITG

Shed at al						Madiantad	2 anxiety			MDD < HC: R IFG, L/R MFG,
	22 (10)	22 (11)	15.00	16.00	NA	Medicated	disorder; 3	1.5T/8 mm	<i>p</i> < 0.05 (FWE)	R SFG, L/R Caudate, R STG,
2012						(n = 4)	ADHD			L Thalamus, L/R Cerebellum
C						N. 1 1			-0.05 0 I	MDD < HC: L Insula, R PHG,
Sprengeimeyer	17 (9)	21 (12)	45.60	42.00	NA	Medicated	0	1.5T/8 mm	<i>p</i> < 0.05 (Monte	L MTG, R SFG, L FFG, R
et al. 2011						(n = 17)			Carlo)	Amygdala
Stratmann et al	122 (76)	132	27.96	27.82	7 70	Medicated	41 anxiety	2T /0	<i>p</i> < 0.05	MDD < HC: R Insula, L SPL,
2014	132 (76)	(74)	37.80	37.82	1.18	(n = 126)	disorder	31/8 mm	(AlphaSim)	L/R STG, L PHG
Straub et al.	(10)	12 (20)	17.00	17.60		Medicated	18			
2019	60 (48)	43 (38)	17.30	17.62	NA	(n = 20)	unspecified	31/6 mm	<i>p</i> < 0.05 (FWE)	MDD > HC: R dIPFC
Treadway et	10 (10)	10 (10)	25.20	20.20	10.00		7 anxiety			
al. 2009	19 (10)	19 (10)	35.20	30.30	12.90	NA	disorder	31/12 mm	<i>p</i> < 0.05 (FWE)	
Ueda et al.			11.20	11.20			0			
2016	30 (13)	48 (13)	44.30	41.20	NA	NA	0	3T/8 mm	<i>p</i> < 0.05 (FWE)	MDD < HC: STG

Wagner et al										caudatus, R IFG, R Subgenual
2011	30 (25)	30 (25)	37.55	35.10	5.59	NA	0	1.5T/12 mm	<i>p</i> < 0.05 (FWE)	cortex, L/R
2011										Hippocampus/amygdala, L
										OFC, L SFG
Wehrv et al							5 ADHD; 1		n < 0.001	MDD > HC: R MFG, L
2015	14 (11)	41 (27)	14.00	13.00	NA	NA	disruptive	4T/8 mm	(uncorr)	Precuneus, R Thalamus, R
2010							behavior		(uncon)	Caudate
										MDD < HC: L/R MFG, L/R
Yang et al.	35 (35)	23 (23)	44.54	39.09	2.68	Drug naïve	NA	3T/8 mm	<i>p</i> < 0.005	Insula, L/R Putamen, R
2017						C			(AlphaSim)	Amygdala, R PHG, L Lingual
										gyrus, Cerebellum
Yüksel et al.	37 (20)	54 (21)	37.90	35.90	NA	Medicated	13 OCD,	3T/NA	<i>p</i> < 0.05 (FWE)	
2018						(n = 28)	somatoform			



Abbreviations: ACC, anterior cingulate cortex; AD, adjustment disorder with mixed disturbance of emotions and conduct; ADHD, attention deficit hyperactivity disorder; AG, agoraphobia; AUD, alcohol use disorder; corr, corrected; dIPFC, dorsolateral prefrontal cortex; dmPFC, dorsomedial prefrontal cortex; FDR, false discovery rate; FFG, fusiform gyrus; FWE, family-wise error; FWHM, full width at half maximum; GRF, Gaussian random field; HC, healthy controls; IFG, inferior frontal gyrus; IOG, inferior occipital gyrus; IPL, inferior parietal lobule; ITG, inferior temporal gyrus; L, left hemisphere; MCC, medial cingulate cortex; MDD, major depressive disorder; MFG, medial frontal gyrus; MOG, middle occipital gyrus; mPFC, medial prefrontal cortex; MTG, middle temporal gyrus; NA, not available; OCD, obsessive-compulsive disorder; OFC, orbitofrontal cortex; PCC, posterior cingulate

or

cortex; PHG, parahippocampal gyrus; R, right hemisphere; SFG, superior frontal gyrus; sgACC, subgenual anterior cingulate cortex; SMA, supplementary motor area; SOG, superior occipital gyrus; SPL, superior parietal lobule; STG, superior temporal gyrus; uncorr, uncorrected; VBM, voxel-based morphometry; vmPFC ventromedial prefrontal cortex.

* Studies that provided original whole-brain *t*-maps.

MNI	SDM Z-	P value Voxels Regions	D 4	Egger's	Egger's p		
coordinates	Score	P value	v oxels	Kegions	ВА	bias	value
GAD > HC							
4, -28, 62	3.411	0.00032	18	R paracentral lobule	4	-0.37	0.832
GAD < HC							
				L insula, rolandic			
44 0 0	2.051	0.000020	411	operculum, heschl	40	0.45	0.007
-44, -8, 8	-3.951	0.000039	411	gyrus, STG,	48	0.45	0.806
				supramarginal gyrus			
22 24 1 0		0.000025	2.15	L IFG, temporal pole,	20/15	0.44	0.000
-32, 24, -10	-3.973	0.000035	247	insula	38/47	-0.41	0.809
-8, -24, 12	-3.694	0.00011	22	L thalamus		0.26	0.878
6, -58, 10	-3.117	0.00091	12	R lingual gyrus	17	0.77	0.697
44, -38, 50	-3.177	0.00074	10	R IPG	2	0.28	0.873
FAD > HC							
12, -70, -12	3.626	0.000144	26	R lingual gyrus	18	-0.01	0.993
-14, -80, -12	3.331	0.000433	20	L lingual gyrus	18	0.05	0.942
SAD > HC							
				L postcentral gyrus,			
-56, -20, 22	3.514	0.000220	147	STG	48	0.26	0.797

Table S4. Whole-brain meta-analysis results for VBM studies in GAD, FAD and MDD at p < 0.0025, uncorrected.

R superior longitudinal

					39/40		
48, -46, 34	3.476	0.000255	91	fasciculus, angular		0.60	0.602
					/48		
				gyrus			
26, -50, 58	3.484	0.000246	66	R SPG	5/7	0.11	0.909
24 56 12	2 6 4 1	0.000126	57	D SEC domolotoral	10	0.05	0.050
24, 30, 12	5.041	0.000130	57	K SFG, dorsolateral	10	0.05	0.939
				L postcentral/precentral			
-20, -32, 62	3.885	0.000051	35	017110	3	-0.08	0.933
				gylus			
				R postcentral gyrus,			
56, -26, 48	3.342	0.000416	20	supramarginal gyrus	2/3	0.03	0.975
				supramarginar gyrus			
-28, -42, -46	3.574	0.000176	19	L cerebellum,		-0.07	0.944
-8 52 12	3 380	0 000363	16	L SFG medial	10	-0.31	0.74
0, 02, 12	2.200	0.000202	10		10	0.01	0.71
14, -68, -10	3.145	0.000829	11	R lingual gyrus	18	0.15	0.874
-128012	3.265	0.000547	11	L lingual gyrus	18	0.56	0.587
, ,							
PD < HC							
38, 0, 8	-3.784	0.000077	63	R Insula	48	-0.79	0.488
, ,							
48, -2, -10	-3.200	0.000687	12	R STG	48	-0.70	0.494
-36, 10, -22	-3.037	0.001195	12	L temporal pole, STG	38	0.09	0.928
MDD < HC							
		0.0000071		R insula, MTG, STG,	48/21		
46, -2, 4	-4.339		877			-0.37	0.405
		53		rolandic operculum	/22		

		53		rolandic operculum	/22		
2 26 10	5 010	0.0000002	700	L/R SFG, medial	11/10	0.54	0.200
2, 36, -10	-5.012		122			-0.54	0.300
		98		orbital, L/R ACG	/32		

10, 6, 40	-3.709	0.0001041 29	118	L/R MCG	32/24	-0.31	0.591
36, -30, -14	-3.115	0.0009192 23	10	R PHG	20	-0.59	0.371

Abbreviations: ACG, anterior cingulate/paracingulate gyri; BA, Brodmann area; FAD, fear-related anxiety disorder; GAD, generalized anxiety disorder; HC, healthy controls; IFG, inferior frontal gyrus; IPG, inferior parietal gyri; ITG, inferior temporal gyrus; L, left hemisphere; MCG, median cingulate/paracingulate gyri; MDD, major depressive disorder; MNI, Montreal Neurological Institute; MTG, middle temporal gyrus; PHG, parahippocampal gyrus; R right hemisphere; SDM, seed-based d mapping; SFG, superior frontal gyrus; SPG, superior parietal gyri; STG, superior temporal gyrus; VBM, voxel-based morphometry.



Figure. S1. Brain regions showing decreased GMV of patient vs healthy controls for studies pooled

across GAD, FAD and MDD. Clusters were displayed at TFCE based FWE corrected p < 0.05.

Supplement References

- 1. Radua J, Mataix-Cols D, Phillips ML, et al.: A new meta-analytic method for neuroimaging studies that combines reported peak coordinates and statistical parametric maps. Eur Psychiatry 2012; 27:605–611
- Radua J, Schmidt A, Borgwardt S, et al.: Ventral Striatal Activation During Reward Processing in Psychosis: A Neurofunctional Meta-Analysis. JAMA Psychiatry 2015; 72:1243–1251
- Albajes-Eizagirre A, Radua J: What do results from coordinate-based meta-analyses tell us? Neuroimage 2018; 176:550–553
- Smith SM, Nichols TE: Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 2009; 44:83–98
- Albajes-Eizagirre A, Solanes A, Vieta E, et al.: Voxel-based meta-analysis via permutation of subject images (PSI): Theory and implementation for SDM. Neuroimage 2019; 186:174–184
- 6. Albajes-Eizagirre A, Solanes A, Fullana MA, et al.: Meta-analysis of voxel-based neuroimaging studies using seed-based d mapping with permutation of subject images (Sdm-psi). J Vis Exp 2019; 2019
- Goodkind M, Eickhoff SB, Oathes DJ, et al.: Identification of a common neurobiological substrate for mental Illness. JAMA Psychiatry 2015; 72:305–315